These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26523292)

  • 1. New prospects for a preventive HIV-1 vaccine.
    Brown J; Excler JL; Kim JH
    J Virus Erad; 2015 Apr; 1(2):78-88. PubMed ID: 26523292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects for a Globally Effective HIV-1 Vaccine.
    Excler JL; Robb ML; Kim JH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
    Kim JH; Excler JL; Michael NL
    Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.
    Wise MC; Hutnick NA; Pollara J; Myles DJ; Williams C; Yan J; LaBranche CC; Khan AS; Sardesai NY; Montefiori D; Barnett SW; Zolla-Pazner S; Ferrari G; Weiner DB
    J Virol; 2015 Sep; 89(18):9154-66. PubMed ID: 26085155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview.
    Girard M; Habel A; Chanel C
    C R Acad Sci III; 1999 Nov; 322(11):959-66. PubMed ID: 10646090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV vaccine efficacy and immune correlates of risk.
    O'Connell RJ; Excler JL
    Curr HIV Res; 2013 Sep; 11(6):450-63. PubMed ID: 24033301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.
    Lee FH; Mason R; Welles H; Learn GH; Keele BF; Roederer M; Bar KJ
    J Virol; 2015 Dec; 89(24):12388-400. PubMed ID: 26423953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
    Silva de Castro I; Gordon SN; Liu J; Bissa M; McKinnon K; Trinh HV; Doster MN; Schifanella L; Liyanage NP; Cao J; Cheng O; Foulds K; Roederer M; Koup RA; Shen X; Tomaras GD; Venzon DJ; Forthal DN; Fouts T; Montefiori DC; Tartaglia J; Rao M; Ostrowski M; Franchini G; Vaccari M
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31896599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
    Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
    AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current views on the potential for development of a HIV vaccine.
    Cohen KW; Frahm N
    Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.